Gary Speier

Carlson Caspers represents Teva in three Inter Partes Reviews [IPR2016-01343; IPR2016-01341; and IPR2016-01340] concerning Teva’s Paragraph IV ANDA challenge of 1 patent covering methods of using the active pharmaceutical ingredient (API) present in the drug pemetrexed sodium (Alimta®). The three IPRs were filed during the related Hatch-Waxman patent litigation and are currently pending.